Management Team

Michael McGarrity

President and Chief Executive Officer

Mr. McGarrity, who has more than 17 years of sales and marketing experience in the medical device industry, joined Nanosphere after 13 years with Stryker Corporation. He served in leadership roles in marketing and strategic development, most recently as vice president of marketing for Stryker Instruments, a $700 million division of the $4.3 billion Stryker Corporation. In this position, McGarrity's marketing and business development acumen guided the company into markets such as post-operative pain management, waste management and interventional pain management which now account for more than 20 percent of the division's revenue. He also had executive general management responsibility for a newly created business focused on interventional pain management. McGarrity is a graduate of the University of Notre Dame and began his career in commercial banking in Chicago.

Roger Moody

Vice President of Finance, Treasurer and Chief Financial Officer

Mr. Moody joined Nanosphere in 2007 as Chief Financial Officer and Vice President of Finance & Administration. He also serves as the Company’s Treasurer and Secretary. Mr. Moody has more than 20 years of experience in leading finance, corporate development and operations for high growth healthcare and technology companies. Previously, Mr. Moody spent six years at Medsn, a medical education company where he joined as chief financial officer and chief operating officer. Mr. Moody also served as chief financial officer and led corporate development for two private venture backed companies sold to strategic partners. Additionally, Mr. Moody provided mergers and acquisition and strategic advisory services to technology and healthcare companies for Volpe Brown Whelan & Company. Mr. Moody began his career at IBM. Mr. Moody received his B.S. from Syracuse University and his M.B.A. from the University of Chicago, Graduate School of Business.

Bill Athenson

Vice President of International Marketing and Business Development

Mr. Athenson joined Nanosphere in January 2002. Mr. Athenson brings to Nanosphere more than 21 years of healthcare experience in clinical diagnostics, medical devices and information technology with Fortune 500 companies such as Baxter, American Scientific Products, Allegiance Healthcare and two start-up technology companies. Before joining Nanosphere in January 2002, Mr. Athenson served as General Manager for Allegiance Healthcare with P&L responsibility for a $120 million revenue base. At Allegiance and in previous leadership positions at Baxter Diagnostics and American Scientific Products, he maintained a consistent track record for leading business development, consulting, and operations teams which consistently achieved double-digit revenue and EBITDA growth in the clinical-laboratory and point-of-care markets. Most recently he headed business development teams in two new technology start-up companies achieving successful launches. Mr. Athenson holds an M.B.A. from Kellogg School of Business and a bachelor's degree from Fordham University.

Mark Del Vecchio

Vice President of Regulatory Affairs

Mark Del Vecchio joined Nanosphere in 2011 as Vice President of Regulatory Affairs with over 20 years of clinical and regulatory experience in the biotechnology and molecular in-vitro diagnostic (IVD) industries. Prior to coming to Nanosphere, Mr. Del Vecchio served as Vice President of Regulatory Affairs for LipoScience, Vice President of Regulatory and Clinical Affairs for Digene Corporation (now Qiagen), Director of Regulatory Affairs in the Food, Drug, Medical Device, and Agriculture practice at Hogan and Hartson, LLP, (now Hogan Lovells) and Manager of Clinical Affairs for Roche Molecular Systems. In these positions, Mr. Del Vecchio has acquired extensive experience interacting with the US Food and Drug Administration (FDA) Office of In-Vitro Diagnostic Device Evaluation and Safety (OIVD) and several international regulatory authorities, having worked predominantly with IVD’s on the leading-edge of diagnostic technology. Mr. Del Vecchio also served as Special Representative to the AdvaMed Board of Directors and as a member of the AdvaMed Diagnostic Sector Technology and Regulation Sub-committee, the Diagnostic Task Force (DTF), and the Genetics/Molecular IVD sub-committee of the DTF. Mr. Del Vecchio holds a Bachelor of Science degree in Biochemistry from the University of Scranton.